Truist Securities Upgrades Corcept Therapeutics to Buy
(Updated - November 6, 2023 6:57 AM EST)Analysts at Truist Securities downgraded Corcept Therapeutics (NASDAQ:CORT) from Hold to Buy with a price target of $38.00 (from $29.00).The...
Buy
or
Corcept News & Analysis
-
-
Canaccord Genuity maintains Corcept at 'buy' with a price target of $37.00
An analyst from Canaccord Genuity maintained Corcept (NASDAQ: CORT) at 'buy' with a price target of $37.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept had...
-
H.C. Wainwright maintains Corcept at 'buy' with a price target of $34.00
An analyst from H.C. Wainwright maintained Corcept (NASDAQ: CORT) at 'buy' with a price target of $34.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept had 4...
-
Corcept earnings beat by $0.06, revenue topped estimates
Investing.com - Corcept (NASDAQ: CORT) reported third quarter EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $123.6M versus the consensus...
-
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications...
-
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications...
-
Corcept Therapeutics Initiates MONARCH Trial
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology...
-
Piper Sandler maintains Corcept at 'overweight' with a price target of $35.00
An analyst from Piper Sandler maintained Corcept (NASDAQ: CORT) at 'overweight' with a price target of $35.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept...
-
Canaccord Genuity maintains Corcept at 'buy' with a price target of $34.00
An analyst from Canaccord Genuity maintained Corcept (NASDAQ: CORT) at 'buy' with a price target of $34.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept had...
-
H.C. Wainwright maintains Corcept at 'buy' with a price target of $32.00
An analyst from H.C. Wainwright maintained Corcept (NASDAQ: CORT) at 'buy' with a price target of $32.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept had 4...
-
Truist Securities maintains Corcept at 'hold' with a price target of $29.00
An analyst from Truist Securities maintained Corcept (NASDAQ: CORT) at 'hold' with a price target of $29.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept...
-
Corcept earnings beat by $0.10, revenue topped estimates
Investing.com - Corcept (NASDAQ: CORT) reported second quarter EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.7M versus the consensus...
-
Corcept Therapeutics Announces Journal of Clinical Oncology Publishes Results of Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and...
-
Truist Securities maintains Corcept at 'hold' with a price target of $26.00
An analyst from Truist Securities maintained Corcept (NASDAQ: CORT) at 'hold' with a price target of $26.00 from a prior price target of %currency%%price%. Prior to this rating, Corcept...
-
Corcept earnings missed by $0.05, revenue topped estimates
Investing.com - Corcept (NASDAQ: CORT) reported first quarter EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $105.7M versus the consensus...
-
SVB Leerink new coverage Corcept Market Perform
A SVB Leerink analyst initiated new coverage Corcept (NASDAQ: CORT) Market Perform rating and a price target of $25.00. Prior to this rating, Corcept had 4 buy ratings, 2 hold ratings,...
-
Piper Sandler new coverage Corcept Overweight
A Piper Sandler analyst initiated new coverage Corcept (NASDAQ: CORT) Overweight rating and a price target of $27.00. Prior to this rating, Corcept had 3 buy ratings, 2 hold ratings, and...
-
Corcept Therapeutics Initiates CATALYST Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and...
-
5 big stock buybacks: Verisk, Con Edison | Pro Recap
By Davit KirakosyanInvesting.com -- Here are 5 biggest share buyback announcements from the past week you may have missed on InvestingPro. Start your free 7-day trial to get this news...
-
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7.5M Shares of its Common Stock
Corcept Therapeutics (NASDAQ:CORT) Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,...
-
Corcept Therapeutics Misses Q4 EPS by 10c
Corcept Therapeutics (NASDAQ:CORT) reported Q4 EPS of $0.14, $0.10 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103.1 million versus the consensus...
-
Corcept earnings missed by $0.10, revenue fell short of estimates
Investing.com - Corcept (NASDAQ: CORT) reported fourth quarter EPS of $0.14, $0.10 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $103.1M versus the consensus...
-
Corcept Therapeutics Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance
Corcept Therapeutics (NASDAQ:CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus...
-
After-Hours Stock Movers 03/30: (OEG) (PRG) (CORT) Higher; (PATH) (EXFY) (MASI) Lower (more...)
After-Hours Stock Movers:UiPath Inc. (PATH) 20% LOWER; reported fourth-quarter EPS of $0.05, versus the consensus of $0.03. Revenue for the quarter came in at $289 million versus the...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.59%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Utilities, Basic Materials and Healthcare sectors propelled shares higher. At the close in NYSE, the Dow...
-
BRIEF-Corcept Therapeutics says Received Paragraph IV Notice Letter Advising Sun Pharmaceutical Industries Submitted ANDA To U.S. FDA
June 11 (Reuters) - Corcept Therapeutics Inc CORT.O :* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING SUN PHARMACEUTICAL INDUSTRIES SUBMITTED ANDA TO U.S. FDA* CORCEPT...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.22%
Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Consumer Goods, Utilities and Healthcare sectors propelled shares higher while losses in the Financials,...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 4.60%
Investing.com – U.S. equities were lower at the close on Monday, as losses in the Healthcare, Financials and Industrials sectors propelled shares lower. At the close in NYSE, the Dow Jones...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
